North America Radioimmunotherapy Market Size, Share, and Growth Forecast 2026 - 2033

The North America Radioimmunotherapy market size is expected to be valued at US$ 883.4 million in 2026 and projected to reach US$ 1,400.1 million by 2033, growing at a CAGR of 6.8% between 2026 and 2033. Rise in cancer incidence, advances in targeted radiopharmaceuticals, growing oncology infrastructure, and adoption of precision medicine are likely to fuel the expansion.

The United States dominates the regional market due to established nuclear medicine facilities, strong clinical research capabilities, and expanding regulatory approvals for radiopharmaceutical therapies. Lutetium-177 (Lu-177) is gaining particular momentum, supported by approved therapies for gastroenteropancreatic neuroendocrine tumors and PSMA-positive prostate cancer. Continued investment in radiopharmaceutical manufacturing, isotope supply, clinical trials, and theranostic platforms is expected to strengthen regional market growth over the forecast period.

Drivers – Growing Cancer Incidence Strengthening Demand for Targeted Radiopharmaceutical Treatment

The escalating burden of cancer across North America remains the foremost driver propelling the radioimmunotherapy market forward. The American Cancer Society estimates that the United States alone will witness well over 2 million new cancer cases in a single year, with non-Hodgkin lymphoma, prostate cancer, and neuroendocrine tumors representing significant treatable populations for radioimmunotherapy and radioligand-based interventions. This growing patient pool is compelling oncology networks and cancer treatment centers to expand access to targeted isotope therapies that selectively destroy malignant cells while minimizing damage to healthy tissue. Companies such as Novartis AG and Curium Pharma continue to scale manufacturing and distribution of radiolabeled therapeutics, reinforcing physician confidence in these treatments as an increasingly mainstream option within modern precision oncology protocols across the region.

Expanding Regulatory Approvals and Clinical Pipeline Broadening Treatment Access

A steadily expanding regulatory pipeline is significantly strengthening the North America Radioimmunotherapy market. The U.S. Food and Drug Administration (FDA) has approved multiple radioligand therapies in recent years, including lutetium-based agents targeting neuroendocrine tumors and prostate cancer, validating the clinical efficacy of radioisotope-conjugated treatments. This regulatory momentum has encouraged pharmaceutical majors such as Eli Lilly and Company, AstraZeneca, and Telix Pharmaceuticals to accelerate late-stage clinical trials and pursue label expansions into additional oncology indications. As more radioimmunotherapy candidates progress through the FDA approval pathway, hospitals and cancer treatment centers gain access to a broader treatment armamentarium, driving increased adoption across academic medical centers and community oncology practices throughout the United States and Canada.

Restraints - Constrained Radioisotope Supply and Complex Manufacturing Infrastructure

Limited global production capacity for medical radioisotopes such as Lutetium-177 (Lu-177) and Yttrium-90 (Y-90) continues to restrain market expansion. Radioisotope production depends on a small number of specialized nuclear reactors and cyclotron facilities, many operated by organizations such as the International Atomic Energy Agency (IAEA)-affiliated networks, creating vulnerability to supply disruptions. Short isotope half-lives further complicate logistics, requiring precise coordination between manufacturers, radiopharmacies, and treatment centers. Any interruption in reactor operations or transportation delays can directly limit patient access to time-sensitive radioimmunotherapy doses, discouraging broader adoption among smaller hospitals and cancer treatment centers that lack dedicated nuclear pharmacy infrastructure to manage such constraints effectively.

High Treatment Costs and Reimbursement Uncertainty Limiting Patient Access

The substantial cost associated with radioimmunotherapy administration, including specialized handling, radiation safety protocols, and hospitalization requirements, represents a persistent restraint on market growth. The Centers for Medicare & Medicaid Services (CMS) reimbursement frameworks for novel radiopharmaceuticals often lag behind FDA approval timelines, creating temporary coverage gaps that limit patient access immediately following product launch. Smaller cancer treatment centers and rural hospitals frequently lack the capital and regulatory licensing needed to establish dedicated radiation safety infrastructure, further concentrating treatment availability within large academic and metropolitan healthcare systems. This uneven access continues to constrain the market's overall penetration across broader patient populations in North America.

 Opportunities - Accelerating Adoption of Lutetium-177 PSMA-Targeted Therapies in Prostate Cancer

The rapid clinical and commercial success of Lutetium-177 (Lu-177) PSMA-targeted radioligand therapies presents a substantial growth opportunity for market participants. Following its FDA approval, Novartis AG's Lu-177 PSMA-617 therapy has demonstrated significant survival benefits in metastatic castration-resistant prostate cancer patients, prompting expanded manufacturing investment and new production partnerships across North America.

Companies such as POINT Biopharma and Lantheus Holdings are actively developing complementary PSMA-targeted diagnostic and therapeutic pairs to support this growing treatment paradigm. As prostate cancer remains one of the most commonly diagnosed malignancies among men in the United States, continued expansion of PSMA-targeted radioligand infrastructure, including dedicated nuclear pharmacy networks and physician training programs, is expected to unlock significant incremental demand for radioimmunotherapy products through 2033.

Emerging Alpha-Emitting Isotope Research Opening New Therapeutic Frontiers

Growing investment in alpha-emitting radioisotopes such as actinium-225 presents a compelling long-term opportunity for radioimmunotherapy developers. Alpha particles deliver highly localized, high-energy radiation with a shorter tissue penetration range than beta-emitters like Yttrium-90 (Y-90), offering the potential for improved tumor cell destruction with reduced damage to surrounding healthy tissue.

Companies including Actinium Pharmaceuticals and Fusion Pharmaceuticals, the latter having advanced its targeted alpha therapy platform under AstraZeneca, are actively progressing clinical programs targeting hematologic and solid tumors. As academic research institutes and specialty manufacturers continue expanding actinium-225 production capacity to address current supply limitations, vendors that secure early access to next-generation alpha-emitter supply chains are well-positioned to capture substantial market share as these therapies progress toward broader regulatory approval and commercialization.

Product Type Analysis

Radioisotope-Based Radioimmunotherapy held the leading position within the product type category, accounting for approximately 64% of the North America Radioimmunotherapy market share in 2025. This dominance is largely attributed to the widespread clinical success of radioligand therapies such as Lu-177 PSMA-617 and Lu-177 DOTATATE, which have achieved strong physician adoption for prostate cancer and neuroendocrine tumor treatment, respectively. Unlike monoclonal antibody-conjugated agents, radioisotope-based formulations generally offer simpler manufacturing scalability and more predictable pharmacokinetics, supporting broader hospital and cancer treatment center adoption.

Continued FDA approvals and expanding production partnerships involving companies such as Novartis AG and ITM Isotope Technologies Munich SE are reinforcing radioisotope-based therapy's leading position, while monoclonal antibody-based radioimmunotherapy continues to serve as an important complementary treatment pathway for hematologic malignancies.

Radioisotope Analysis

Lutetium-177 (Lu-177) emerged as the leading radioisotope segment, capturing approximately 39% of the North America Radioimmunotherapy market share in 2025. Lu-177's favorable half-life, moderate-energy beta emission, and compatibility with peptide receptor and small-molecule targeting agents have made it the isotope of choice for recently approved therapies addressing neuroendocrine tumors and metastatic prostate cancer.

Expanding domestic production capacity, supported by facilities affiliated with organizations such as the U.S. Department of Energy, has helped stabilize Lu-177 supply chains relative to historically constrained isotopes. Meanwhile, Yttrium-90 (Y-90) is projected to be the fastest-growing radioisotope segment through 2033, driven by expanding use in liver-directed radioembolization and emerging hematologic cancer applications supported by companies including Y-mAbs Therapeutics.

Target Antigen Analysis

PSMA represented the leading target antigen segment, accounting for approximately 41% of the North America Radioimmunotherapy market share in 2025, driven by the strong commercial performance of PSMA-targeted lutetium-177 therapies in metastatic prostate cancer. Prostate-specific membrane antigen is highly overexpressed on prostate tumor cells, enabling precise radioligand binding and minimal off-target toxicity, a characteristic that has supported rapid physician adoption following FDA approval.

Continued clinical investment from companies such as Novartis AG, Lantheus Holdings, and POINT Biopharma in PSMA-targeted diagnostic and therapeutic pairs is reinforcing this segment's leadership, while HER2-targeted radioimmunoconjugates are gaining momentum as the fastest-growing target antigen category, supported by emerging clinical programs addressing HER2-positive breast and gastric cancers across North American research institutes.

End User Analysis

Cancer Treatment Centers led the end-user category, accounting for approximately 46% of the North America radioimmunotherapy share in 2026, owing to their specialized nuclear pharmacy infrastructure, radiation safety licensing, and dedicated oncology staff trained in radioisotope handling protocols. These centers are typically better equipped than general hospitals to manage the logistical complexity of short-half-life isotopes such as Lutetium-177 (Lu-177) and Yttrium-90 (Y-90), enabling faster patient scheduling and dose administration.

According to treatment volume trends reported by the American Society of Clinical Oncology (ASCO), dedicated cancer centers continue to account for a disproportionate share of radioligand therapy administrations. Hospitals represent the fastest-growing end-user segment through 2033, as expanding nuclear medicine departments and academic medical center partnerships broaden radioimmunotherapy access beyond specialized treatment facilities.

North America Radioimmunotherapy Market Trends and Insights

The North America radioimmunotherapy market benefits from advanced nuclear medicine infrastructure, strong regulatory support from the FDA, and a concentrated presence of leading radiopharmaceutical developers including Novartis AG, Lantheus Holdings, and Telix Pharmaceuticals. Robust reimbursement pathways through the Centers for Medicare & Medicaid Services (CMS), combined with growing academic research collaboration and expanding isotope production capacity, continue to strengthen regional treatment access.

Rising clinical trial activity targeting prostate cancer, neuroendocrine tumors, and hematologic malignancies further reinforces North America's position as the most clinically advanced and commercially mature radioimmunotherapy market globally, with continued expansion expected through 2033 as additional radioligand therapies progress through regulatory review.

U.S. Radioimmunotherapy Market Size

The United States dominated the North America radioimmunotherapy market, accounting for approximately 88% share in 2026, supported by the highest concentration of FDA-approved radioligand therapies, extensive academic cancer center networks, and strong presence of key manufacturers such as Novartis AG and Lantheus Holdings. Favorable CMS reimbursement policies and continued investment in domestic isotope production infrastructure, including facilities linked to the U.S. Department of Energy, have further reinforced sustained treatment adoption across hospitals and specialized cancer treatment centers nationwide.

Canada Radioimmunotherapy Market Size

Canada represented the fastest-growing country within North America radioimmunotherapy, driven by expanding nuclear medicine capacity and continued isotope production supported by Canadian reactor facilities historically significant to global medical isotope supply. Growing collaboration between Canadian academic research institutes and international radiopharmaceutical developers, alongside provincial health authority investment in oncology infrastructure, is accelerating access to radioligand and radiolabeled antibody therapies, positioning the country for above-average regional growth in the coming years.

The North America Radioimmunotherapy market is moderately consolidated, with established radiopharmaceutical developers such as Novartis AG, Bayer AG, and Eli Lilly and Company competing alongside specialized innovators including Telix Pharmaceuticals, POINT Biopharma, and Fusion Pharmaceuticals. Market leaders are differentiating through continued investment in isotope supply chain security, expanded manufacturing partnerships, and diversified radioligand pipelines targeting multiple tumor types.

Strategic acquisitions, such as major pharmaceutical companies acquiring specialized radiopharmaceutical developers to secure proprietary isotope-conjugation platforms, remain a dominant growth strategy. Emerging business models increasingly favor vertically integrated manufacturing and distribution networks, allowing companies to control isotope production, radiopharmacy logistics, and clinical delivery, reflecting the industry's broader shift toward supply chain resilience amid ongoing radioisotope availability constraints across North America.

Key Developments:

• In April 2025, Debiopharm and Oncodesign Services launched a strategic collaboration to advance preclinical research in radiopharmaceuticals and radioimmunotherapy. The partnership combines Debiopharm’s AbYlink™ regio-selective bioconjugation technology with Oncodesign Services’ preclinical expertise to develop antibody–chelator conjugates for targeted molecular radiotherapy.
• A 2026 Journal of Nuclear Medicine study evaluated DLL3-directed Ac-225 radioimmunotherapy in neuroendocrine lung and prostate cancer models, highlighting the potential of alpha-emitting radionuclides for targeted cancer treatment.